Capricor Therapeutics, Inc. CAPR 深 滬
等待開盤 09-08 09:30:00 美东时间
9.40
+0.120
+1.29%
華盛通- 最 高9.81
- 今 開9.40
- 成交量 255.55万股
- 最 低 9.26
- 昨 收 9.28
- 總市值 5.47亿
- 52周最高 40.37
- 市盈率 靜 --
- 換手率 4.40%
- 52周最低 2.96
- 委 比 -65.85%
- 總股本 5813.90万
- 歷史最高 171.50
- 量 比 0.51
- 振 幅 5.93%
- 歷史最低 0.88
- 每 手 1
- 風險率 10.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 美银上调微软目标价从500美元升至600美元；BlossomHill获小摩等多家大行首予买入评级
今日重点评级关注：BTIG：维持Kazia Therapeutics"买入"评级，目标价从34美元升至40美元；摩根大通：维持Annexon"超配"评级，目标价从10美元升至14美元
09-02 14:07
Piper Sandler Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $25
Piper Sandler analyst Edward Tenthoff upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $2 to $25.
09-02 00:46
Capricor wins another upgrade on Deramiocel review extension
Shares of Capricor Therapeutics (CAPR) gained on Tuesday as Piper Sandler became the latest brokerage to upgrade the biopharma after the FDA’s recent decision to extend the review period for its lead ...
09-01 22:43
美股牛股 | 业绩股获资金追捧！爱芬奇飙升35.7%，BOSS直聘升近16%；Biohaven劲升17.9%，斩获近8亿美元许可协议
亮眼财报成“吸金石”！爱芬奇绩后飙升35.7%，全年EPS指引上调至最高13.6美元；BOSS直聘升近16%，宣布2.3亿美元派息计划；Biohaven劲升17.9%，获7.95亿美元许可协议。
08-27 15:41
美股牛股 | Capricor飙近22%，获大行上调目标价至54美元；机器人股RR、稀土概念股Critical Metals双双升逾21%
Capricor隔夜飙升21.9%，获大行上调目标价至54美元；Richtech Robotics升21.6%，宣布1200万美元股票回购计划；稀土概念股Critical Metals劲升21.4%>>
08-26 19:31
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Nasdaq Composite gaining around 150 points on Tuesday. Shares of Nayax Ltd (NASDAQ:NYAX) rose sharply during Tuesday’s session after the payments company agreed to acquire smart parking technology provider IPS Group Inc. for $350 million in cash. Nayax will acquire ...
08-25 22:03
Capricor upgraded at Oppenheimer as Deramiocel review extended
Following an over 8% jump in the previous session, shares of Capricor Therapeutics (CAPR) continued to rise in premarket trading on Tuesday as Oppenheimer upgraded the biotech after the FDA extended t...
08-25 20:26
Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion
Shares of Biomea Fusion Inc (NASDAQ:BMEA) are trading sharply higher on Monday following an operational milestone for its lead metabolic drug program. Here’s what investors need to know. Biomea Fusion shares are powering higher. What’s behind BMEA gains? COVALENT-211 Reaches Full Enrollment With Top...
08-25 04:05
Why Is Capricor Therapeutics Stock Trading Higher on Monday?
Capricor Therapeutics Inc (NASDAQ:CAPR) stock is trading higher on Monday as investors react to the FDA’s continued review of deramiocel update. The U.S Food and Drug Administration (FDA) extended the PDUFA target action date for deramiocel, setting a new target of November 22. Investors are probabl...
08-25 01:48
Capricor rises as FDA extends Deramiocel action date
Capricor Therapeutics (CAPR) is up ~7% in Monday morning trading after announcing that the FDA has extended the action date for its BLA on Duchenne muscular dystrophy therapy Deramiocel by three month...
08-24 22:27
